CC
MACK

Cannell & Co’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Cannell & Co’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-63,499
Closed -$347K – 255
2019
Q1 		$347K Hold
63,499
– – 0.01% 205
2018
Q4 		$193K Sell
63,499
-32,292
-34% -$112K 0.01% 232
2018
Q3 		$402K Hold
95,791
– – 0.01% 212
2018
Q2 		$370K Hold
95,791
– – 0.01% 214
2018
Q1 		$607K Sell
95,791
-128
-0.1% -$1.06K 0.02% 192
2017
Q4 		$774K Sell
95,919
-14,105
-13% -$132K 0.03% 186
2017
Q3 		$1.26M Sell
110,024
-26,838
-20% -$282K 0.04% 160
2017
Q2 		$1.33M Sell
136,862
-17,244
-11% -$352K 0.05% 154
2017
Q1 		$3.73M Sell
154,106
-45,820
-23% -$1.15M 0.13% 120
2016
Q4 		$6.42M Sell
199,926
-4,918
-2% -$210K 0.23% 95
2016
Q3 		$10.2M Sell
204,844
-382
-0.2% -$15.9K 0.37% 73
2016
Q2 		$8.7M Buy
205,226
+55,632
+37% +$3.03M 0.32% 78
2016
Q1 		$9.85M Buy
149,594
+15,989
+12% +$835K 0.35% 70
2015
Q4 		$7.75M Hold
133,605
– – 0.25% 83
2015
Q3 		$8.95M Hold
133,605
– – 0.29% 82
2015
Q2 		$13M Buy
133,605
+90,810
+212% +$8.64M 0.37% 72
2015
Q1 		$4M Buy
42,795
+1,271
+3% +$108K 0.12% 120
2014
Q4 		$3.69M Buy
41,524
+33,212
+400% +$2.42M 0.11% 117
2014
Q3 		$574K Buy
8,312
+1,271
+18% +$67.9K 0.02% 200
2014
Q2 		$404K Buy
7,041
+3,558
+102% +$181K 0.01% 212
2014
Q1 		$138K Hold
3,483
– – ﹤0.01% 267
2013
Q4 		$146K Buy
+3,483
New +$101K 0.01% 118

Other funds holding MACK

2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $292M AUM 36.12% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Cannell & Co's MACK Position: Q2 2019 in Review

Cannell & Co sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2019, closing a stake of 63,499 shares — an estimated $347K sold.

Cannell & Co first reported a position in MACK in Q4 2013 and held it in 22 quarters. The position peaked at $13M in Q2 2015. 50 funds tracked by Wall St. Rank hold MACK as of Q2 2019.

  • Cannell & Co reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Cannell & Co sold 63,499 Merrimack Pharmaceuticals, Inc. shares in Q2 2019, an estimated $347K.
  • Cannell & Co first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2013 and held it in 22 quarters.
  • Cannell & Co's Merrimack Pharmaceuticals, Inc. position peaked at $13M in Q2 2015.
  • 50 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2019.

Based on Cannell & Co's 13F filing for Q2 2019, filed 12 Aug 2019.